论文部分内容阅读
目的:了解表浅性膀胱癌患者术后口服人参皂甙Rg3(SPG Rg3)联合丝裂霉素C(MMC)膀胱内灌注后血清中血管内皮细胞生长因子(VEGF)的浓度并探讨其临床意义。方法:将65例表浅性膀胱癌患者随机分为MMC治疗组和MMC+人参皂甙Rg3治疗组。采用流式细胞仪测定2组患者术前、辅助治疗前及辅助治疗后2个月血清VEGF浓度,同时测定30例健康成人血清VEGF浓度。结果:术前表浅性膀胱癌患者血清VEGF水平(258.0±185.1)pg.mL-1明显高于健康成人(163.1±95.5)pg.mL-1(P<0.01);辅助治疗后2个月Rg3+MMC治疗组血清VEGF水平(183.8±107.1)pg.mL-1明显低于单纯MMC治疗组(246.4±177.5)pg.mL-1(P<0.05)。结论:表浅性膀胱癌患者血清VEGF水平明显高于健康人,血清VEGF水平可作为反映表浅性膀胱癌生物学行为的指标之一;采用口服人参皂甙Rg3联合MMC膀胱内灌注能明显降低表浅性膀胱癌患者术后血清VEGF水平,从而有可能进一步降低表浅性膀胱癌的复发率。
Objective: To investigate the serum concentration of vascular endothelial growth factor (VEGF) in patients with superficial bladder cancer after oral ginsenoside Rg3 (SPG Rg3) and mitomycin C (MMC) intravesical instillation and to investigate its clinical significance. Methods: 65 patients with superficial bladder cancer were randomly divided into MMC treatment group and MMC + ginsenoside Rg3 treatment group. Flow cytometry was used to measure serum VEGF concentrations in the two groups before operation, before adjuvant therapy and 2 months after adjuvant therapy, and serum VEGF concentrations were measured in 30 healthy adults. Results: The serum level of VEGF (258.0 ± 185.1) pg.mL-1 in patients with superficial bladder cancer before operation was significantly higher than that in healthy adults (163.1 ± 95.5) pg.mL-1 (P <0.01) Serum VEGF level (183.8 ± 107.1) pg.mL-1 in Rg3 + MMC group was significantly lower than that in MMC group (246.4 ± 177.5) pg.mL-1 (P <0.05). Conclusions: Serum VEGF level in patients with superficial bladder cancer is significantly higher than that in healthy people. Serum VEGF level can be used as one of the indicators to reflect the biological behavior of superficial bladder cancer. Oral ginsenoside Rg3 combined with intravesical instillation of MMC can significantly decrease the level of VEGF Shallow bladder cancer patients with serum VEGF levels, which may further reduce the recurrence of superficial bladder cancer.